

eMind and St. Marianna University Sign Comprehensive Partnership: Driving Next-Generation Medical Innovation in SaMD and Non-SaMD via Proprietary AI

Combining patented AI technology using digital biomarkers with the University's extensive clinical expertise, the partnership aims to accelerate next-generation medical innovation and the real-world implementation of digital health solutions — from early detection of undiagnosed and untreated populations to real-world evidence accumulation and addressing drug lag and drug loss.

eMind, Inc. (Headquarters: Chiyoda-ku, Tokyo; Chief Executive Officer: David Liebreich; hereinafter “eMind”) and St. Marianna University School of Medicine (Location: Kawasaki City, Kanagawa; President: Hiroaki Kitagawa; hereinafter “St. Marianna University”) have concluded a comprehensive partnership agreement with the aim of leveraging clinical and other data held by St. Marianna University to bring digital health applications developed by eMind to broader social benefit.

A signing ceremony was held on April 22, attended by Hiroaki Kitagawa, President of St. Marianna University; Yoshihisa Yamano, Professor & Chair of Neurology; Atsuo Nakagawa, Professor & Chair of Neuropsychiatry; and David Liebreich, Chief Executive Officer of eMind.




(Image, left to right: eMind Chief Executive Officer David Liebreich; St. Marianna University President Hiroaki Kitagawa)

Accelerating Healthcare DX and New Approaches Enabled by eMind's Proprietary AI Technology

Japan currently faces structural challenges, including a shortage of medical resources and growing fiscal pressure on the healthcare system, driven by the rapid progression of a super-aging society. In this context, there is an urgent need to advance the sharing of medical information through digital technology and to promote PHR (Personal Health Record) initiatives that empower patients to manage and utilize their own health data. Embedding mechanisms for early disease detection and prevention into society has become one of the most critical priorities in Japanese healthcare.

eMind has been researching and developing patented AI technology that derives digital biomarkers from passively collected smartphone data and uses them to predict disease. This approach — grounded in real-world data obtained from daily life — is distinguished by its ability to continuously acquire data while minimizing patient burden, and has the potential to serve as a foundation for generating new evidence through monitoring outside clinical settings.

This partnership will integrate eMind's proprietary AI technology with St. Marianna University's extensive clinical data and advanced clinical expertise to support disease identification and early detection among previously hard-to-reach populations — those who have not yet sought medical consultation or have not yet been diagnosed. The continuous acquisition of behavioral data will also enable objective understanding of patients' physical and mental states, including during care gaps between clinic visits, thereby supporting treatment monitoring and patient care. In addition, the partnership will pursue the ongoing accumulation of high-quality real-world evidence (RWE) through the establishment and operation of disease registries.



Toward Next-Generation Medical Innovation in SaMD and Non-SaMD Fields

Building on these initiatives, the partnership aims — over the longer term — to develop Software as a Medical Device (SaMD) that complements or serves as an alternative to conventional pharmacotherapy, and to address drug lag and drug loss through support for decentralized clinical trials (DCTs) and post-marketing surveillance. The scope of innovation envisioned by this partnership extends beyond the

SaMD domain to encompass wellness and preventive care in the Non-SaMD field as well.

With the improvement of patient QOL and satisfaction positioned as a highest priority alongside the advancement of healthcare quality, the two organizations will accelerate the real-world implementation of digital health solutions rooted in everyday life. Both parties will also devote concerted effort to cultivating the next generation of healthcare professionals through active personnel exchange and educational support between industry and academia.

Going forward, eMind and St. Marianna University will work in close coordination to make the fullest use of their combined human, material, and intellectual resources, contributing to the further advancement of medicine and healthcare in Japan and to the realization of a society in which everyone can live in good health.



(Group photo of eMind and St. Marianna University representatives. Left: Yoshihisa Yamano, Professor and Chair of Neurology; Right: Atsuo Nakagawa, Professor and Chair of Neuropsychiatry)